Entera Bio LtdNASDAQ:ENTX
- LAST PRICE1.6400
- TODAY'S CHANGE (%)-0.0600 (-3.5294%)
- Bid / Lots1.6200/ 10
- Ask / Lots1.8000/ 1
- Open / Previous Close1.6800 / 1.7000
- Day Range
- 52 Week Range
- Volume6,238
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ENTX |
|---|---|---|
| 09:32 ET | 432 | 1.68 |
| 09:44 ET | 300 | 1.718 |
| 10:04 ET | 700 | 1.74 |
| 10:15 ET | 100 | 1.65 |
| 10:22 ET | 1000 | 1.674 |
| 10:33 ET | 1500 | 1.7084 |
| 12:06 ET | 100 | 1.62 |
| 12:12 ET | 180 | 1.67 |
| 12:24 ET | 100 | 1.65 |
| 12:39 ET | 1000 | 1.66 |
| 12:53 ET | 100 | 1.66 |
| 01:00 ET | 100 | 1.64 |
Nov 11, 2024
DJ Entera Bio Price Target Maintained With a $10.00/Share by HC Wainwright & Co., from 7:08AM ET on Monday Nov 11, 2024 by Dow Jones
7:08AM ET on Monday Nov 11, 2024 by Dow Jones
Nov 8, 2024
Entera Bio Reports Q3 2024 Financial Results and -2-, from 4:05PM ET on Friday Nov 08, 2024 by Dow Jones
4:05PM ET on Friday Nov 08, 2024 by Dow JonesPress Release: Entera Bio Reports Q3 2024 Financial Results and Provides Business Updates, from 4:05PM ET on Friday Nov 08, 2024 by Dow Jones
4:05PM ET on Friday Nov 08, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Entera Bio Ltd | 62.6M | -6.3x | --- |
Allovir Inc | 62.5M | -0.6x | --- |
Protara Therapeutics Inc | 62.7M | -1.1x | --- |
Aileron Therapeutics Inc | 59.4M | -0.9x | --- |
Boundless Bio Inc | 59.3M | -1.0x | --- |
Immuneering Corp | 66.1M | -1.1x | --- |
Company Information
Entera Bio Ltd is an Israel-based clinical-stage biopharmaceutical company focused on the development and commercialization of orally delivered large molecule therapeutics for use in areas with unmet medical need and where adoption of injectable therapies is limited due to cost, convenience and compliance challenges for patients. The Company developed a platform that enables the oral delivery of injectable proteins and large molecules. Entera Bio candidates are EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism. Both EB613 and EB612 are oral formulations of human parathyroid hormone (1-34), or Parathormon (PTH). The products are administered via injection.
Contact Information
- Headquarters
- Hadassah / Jerusalem Bio Park, 5th FloorJERUSALEM, Israel 9112002
- Phone
- ---
- Fax
- ---
Executives
- Independent Chairman of the Board
- Gerald Lieberman
- Chief Executive Officer, Director
- Miranda Toledano
- Chief Financial Officer
- Dana Yaacov-Garbeli
- Chief Operating Officer
- Hillel Galitzer
- Chief Financial Officer - United States
- Ramesh Ratan
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $62.6M |
|---|---|
Revenue (TTM) | $99.0K |
Shares Outstanding | 36.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.57 |
EPS | $-0.26 |
Book Value | $0.29 |
P/E Ratio | -6.3x |
Price/Sales (TTM) | 632.5 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -9,304.04% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
